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Abstract Imaging plays an essential role in research on
neurological diseases in the elderly. The Rotterdam Scan
Study was initiated as part of the ongoing Rotterdam Study
with the aim to elucidate the causes of neurological disease
by performing imaging of the brain in a prospective pop-
ulation-based setting. Initially, in 1995 and 1999, random
subsamples of participants from the Rotterdam Study
underwent neuroimaging, whereas from 2005 onwards
MRI has been implemented into the core protocol of the
Rotterdam Study. In this paper, we discuss the background
and rationale of the Rotterdam Scan Study. Moreover, we
describe the imaging protocol, image post-processing
techniques, and the main findings to date. Finally, we
provide recommendations for future research, which will
also be topics of investigation in the Rotterdam Scan
Study.
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Introduction
Neurologic diseases in the elderly, such as dementia and
stroke, will pose an ever increasing burden on societies
over the next couple of decades [1–4]. Yet, effective
therapeutic or preventive strategies are still lacking. In
order to develop such strategies, knowledge on the etiology
of these diseases is crucial. An important feature of neu-
rodegenerative diseases is that structural and functional
brain changes may be already present years before clinical
onset and can be visualized using magnetic resonance
imaging (MRI) [5–10].
Realizing this potential benefit, already in the 1990s,
neuroimaging was implemented in several population-
based studies to study the preclinical brain changes that
ultimately lead to or may indicate an increased risk of
developing clinically manifest diseases, such as dementia
and stroke [7, 11–19]. However, in most of these studies
neuroimaging was only performed in a subset of the pop-
ulation, resulting in limited sample sizes. More impor-
tantly, during the last two decades MR imaging has
undergone huge improvements in hardware and software
leading to higher field strengths, higher resolution, shorter
scanning times, and more sensitive sequences. In addition,
digital image analysis techniques have led to a new field of
research aimed at automating and increasing through-put of
image processing for better visualization and quantification
of imaging findings. Taken together, these developments
now allow for performing neuroimaging in larger sample
sizes and using state-of-the-art imaging and processing
techniques. In turn, this has paved the way for more in
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depth and thorough investigation of (more subtle) brain
changes that can lead to neurological diseases.
It was in this light, that in 1995 the Rotterdam Scan
Study was initiated to investigate risk factors and risk
indicators of neurological diseases in the elderly using MR
imaging to visualize the underlying brain changes and
brain pathology. In 1995 and 1999, random subsamples of
Rotterdam Study participants underwent neuroimaging in
clinical scanners. From 2005 onwards, the Rotterdam Scan
Study has been embedded within the core protocol of the
Rotterdam Study [20], and a dedicated research scanner
was installed in the Rotterdam Study research center.
In the current paper, we provide a general outline of the
study population, scanning protocol, image post-processing
and a discussion of the main findings of the Rotterdam
Scan Study, with the main focus on the period from 2005 to
2015.
Design and study population
The source population of the Rotterdam Scan Study origi-
nates from the Rotterdam Study [21], a population-based
study in the Netherlands that aims to investigate causes and
determinants of chronic diseases in the elderly. The Rot-
terdam Study (RS I) was initiated in 1990 with 7983 par-
ticipants aged 55 years and over, who were interviewed and
underwent physical exam at baseline and during follow-up
visits every 3–4 years. In 2000, the cohort was extended
with 3011 persons (RS II), who were aged 55 and over at that
time. In 2006 the cohort was further extended with 3932
persons aged 45 years and over (RS III). The whole cohort
undergoes re-examinations every 3–4 years. The total Rot-
terdam Study population encompasses 14,926 persons.
Figure 1 shows an overview of the various Rotterdam
Study cohorts, the time of their (re-)examination visits, and
the implementation of MRI-scanning in the core protocol
of the Rotterdam Study in 2005. Initially, we invited ran-
dom persons from the second visit of RS II to undergo
MRI. Subsequently, we have scanned all eligible and
consenting participants from the first visit of RS III and
fifth visit of RS I. Currently, persons from the fourth visit
of RS II are undergoing scanning. Of all persons taking part
in the Rotterdam Study, those with MRI contra-indications
are considered not eligible for the Rotterdam Scan Study.
Furthermore, persons suffering from claustrophobia are
also not included. Because the throughput of performing
MR imaging has been higher than that of the Rotterdam
Study (56 MRI slots per week versus 36 slots for regular
study center visits), we were able to invite additional
subsets for re-scanning. As such, we re-invited participants
from RS I in 2006, RS II in 2008, and RS III in 2010
outside their regular visits for the Rotterdam Study. As a
result, some of the participants are already undergoing their
fourth MRI-exam.
Therefore, as of July 2015, a total of 12,174 brain MR-
scans have been obtained on the research scanner in over
5800 individuals.
Scan protocol
In 2005, a 1.5T MRI unit (General Electric Healthcare,
Milwaukee, USA, software version 11x), dedicated to the
Rotterdam Scan Study, was installed in the Rotterdam
Study research center. Besides the possibility of high
throughput image acquisition, this enabled us to leave
acquisition parameters unchanged by excluding software or
hardware upgrades in order to ensure data stability and
comparability over time. The MRI unit was fitted with a
dedicated 8-channel head coil (best coil configuration
available at time of installation) and the possibility for
parallel imaging using the array spatial sensitivity encoding
technique (ASSET).
Maximum total examination time (from arrival of one
participant in the MRI suite until the next) was initially set
at 45 min, in order to accommodate the MRI acquisition
into the generic workflow of the Rotterdam Study. Later,
this became 50 min due to the addition of a resting-state
functional MRI sequence (rs-fMRI), which is discussed in
detail below.
In the current scan-protocol we carefully balanced the
restrictions of time, costs and inconvenience for the par-
ticipants with the relevance and quality of the acquired
imaging data. To ensure participant compliance and
reproducible image quality (reduce motion artefacts) an
acquisition limit of 6 min per sequence was chosen.
To facilitate easier applicability of the current MRI
protocol by radiology technicians, we chose to use the
standard brain imaging package delivered by the system
manufacturer instead of custom developed sequences.
The MRI sequences were chosen based on the primary
variables of interest, i.e.:
1. quantitative measures of brain tissue volumes and
volumes of various neurostructures (e.g. hippocampus)
2. quantitative assessment of white matter lesions
(WMLs),
3. qualitative assessment of brain infarcts (lacunar and
cortical) and microbleeds,
4. quantitative assessment of white matter microstructural
integrity and connectivity,
5. quantitative assessment of total cerebral blood flow,
6. quantitative assessment of functional brain networks.
In designing the protocol, we tried to meet both the time
constraint and the contrast and resolution requirements.
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When possible, we preferred 3D over 2D sequences
because of higher signal-to-noise ratio (SNR), which
enables the acquisition of smaller voxel sizes. Yet, acqui-
sition time, sensitivity to motion and blurring artefacts did
not allow 3D acquisition in all sequences. For each
sequence, we adjusted the imaging parameters during
optimization procedures to obtain a specific target resolu-
tion with adequate SNR (C25) for tissues in the center of
the brain while scan time was limited to 6 min for each
sequence.
Since mid-2011, the structural MRI protocol has been
extended with a resting-state functional MRI (rs-fMRI)
sequence, further described below. Despite the original aim
to limit scan time to 6 min per sequence, this functional
scan requires 8 min to obtain adequate resting-state data.
The resulting protocol is presented in Table 1 with all
the relevant imaging parameters and the execution order
listed. The protocol starts with a three-plane localizer,
executed with the shimming option enabled. For subse-
quent sequences shimming is turned off to accelerate
receiver adjustments. Morphological imaging is performed
with T1-weighted (T1w), proton density-weighted (PDw)
and fluid-attenuated inversion recovery (FLAIR) sequen-
ces. The combination of different MR contrasts provided
by these sequences can be used for automated segmenta-
tion of brain tissue and WMLs (see section on processing).
For the purpose of segmentation, the T1w scan is acquired
in 3D at high in-plane resolution and with thin slices (voxel
size\ 1 mm3). A 3D T2*-weighted gradient-recalled echo
(GRE) scan is used to image cerebral microbleeds. For this
sequence a TE[ 30 ms was selected to obtain stronger
T2*-weighting. For registration purposes, the same slice
thickness with a lower in-plane resolution as compared to
the 3D T1w scan is used. Parallel imaging is applied for
this sequence to stay within the 6 min scan time limit.
Diffusion tensor imaging (DTI) is used to quantitatively
assess white matter microstructural integrity [22, 23]. For
this 2D DTI scan, we use an echo planar imaging (EPI)
readout with gradients (b = 1000 s/mm2) applied in 25
directions [22, 23]. The b = 0 s/mm2 image is collected
with NEX = 3. The number of gradient directions, i.e. 25,
was chosen to best fit the optimized protocol by Jones et al.
[22, 23] whilst remaining within time limits and maximum
number of slices permitted by the scanner. To minimize
geometrical distortions, the number of frequency encoding
points was set to 64 and parallel imaging was applied with
an acceleration factor of 2, with an imaging matrix of
64x96, providing a voxel size of 3.3 9 2.2 9 3.5 mm3.
Fig. 1 Overview of the sub-cohorts and examination visits of the
Rotterdam Study, and imaging visits of the Rotterdam Scan Study.
Boxes indicate examination visits of the three cohorts of the
Rotterdam Study. Boxes with solid colors indicate visits, during
which MRI imaging was conducted as part of the core protocol.
Examination visits indicated with an ‘X’ indicate extra visits during
which only MRI was performed. The red vertical line indicates the
implementation of MRI on site in the core protocol of the Rotterdam
Study. In 1995 and 1999 (indicated with *) 567 persons underwent
MRI as part of the Rotterdam Scan Study outside the core protocol of
the Rotterdam Study. ‘Total’ indicates the total number of persons
taking part in that Rotterdam Study examination visit. ‘N’ indicates
the number of persons that were eligible (no MRI contra-indications
and no claustrophobia) and invited to take part in the Rotterdam Scan
Study. ‘n’ indicates the number of persons that underwent brain MRI
in the Rotterdam Scan Study
The Rotterdam Scan Study: design update 2016 and main findings 1301
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An ungated 2D GRE phase contrast flow measurement
is applied for assessment of total cerebral blood flow [24],
which has shown to be fast and accurate [24]. A 2D thick
slab projection phase contrast angiographic localizer
(60 mm thick, velocity encoding (VENC) = 60 cm/sec) is
positioned sagittally to determine the location of the carotid
and basilar arteries. Next a thin slice perpendicular to all
three vessels at the level of the precavernous internal car-
otid artery is positioned (VENC = 120 cm/s, slice thick-
ness 5 mm, NEX = 8). Flow velocity data can be
calculated from the phase difference images as described
before [24]. For rs-fMRI, subjects are instructed to lie still
with their eyes open, and not to fall asleep. T2*-weighted
echo planar images (EPIs) are acquired with 3.3 mm iso-
tropic voxels, and a total of one-hundred sixty volumes.
Figure 2 illustrates an example of the different sequen-
ces acquired in the final protocol. The sequence acquisition
order was chosen in a way to provide adequate recon-
struction speeds and to eliminate delays. The 3D T2*w
GRE scan was the last sequence executed in the protocol
pipeline because of the long reconstruction time necessary
for parallel imaging and the resulting lag time in scan
execution.
For quality check, a daily quality assessment (measuring
transmit gain, center frequency and SNR) is performed by
technicians using a phantom. Additionally, weekly mea-
surements of echo-planar stability, isocenter reliability and
accuracy of absolute scaling along the cardinal axes (x,y,z)
are performed. Regular scanner maintenance is performed
by the manufacturer and results are filed in a log.
Furthermore, interscan reproducibility measurements
have been performed by re-inviting study participants
(n = 20–30) within on average 2 weeks after initial
examination for repeat MRI.
Image processing
Within the context of the Rotterdam Scan Study, a stan-
dardized image analysis workflow is being developed,
validated and applied to all imaging data, to enable the
objective, accurate, and reproducible extraction of relevant
parameters describing brain anatomy, possible brain
pathologies, and structural and functional brain connec-
tivity from multispectral MRI data. In the following para-
graphs, we briefly describe the different quantitative image
analysis methods that have been developed and/or
employed within the Rotterdam Scan Study.
Image pre-processing
Prior to analysis, a number of pre-processing steps are
performed. For multispectral image analysis, the different
scans are spatially registered using rigid registration.
Subsequently, the brain is extracted from the scan. Hereto a
manually segmented brain mask—which excludes among
other things, the cerebellum, the eyes, and the skull—is
non-rigidly registered to the T1-weighted image using
Elastix [25].
Finally, scans are corrected for intensity non-uniformity
using the N3 method [26]; non-uniformity correction is
carried out within the brain mask.
Brain tissue segmentation
Automated brain tissue segmentation on MRI has received
considerable attention [11, 27–32]. An important distinc-
tion that can be made is whether methods are supervised
(i.e. they depend on annotated training data), or unsuper-
vised. In the Rotterdam Scan Study, we use a supervised
approach, based on k-nearest neighbour (kNN) segmenta-
tion. In kNN segmentation, image voxels are assigned
labels (grey matter (GM), white matter (WM), cere-
brospinal fluid (CSF) or background (BG)) based on the
most similar voxels in the training data. Similarity here
depends on the distance in normalized MR image intensi-
ties. We have both investigated segmentation based on
T1w images, and multispectral MRI data (T1w and PDw
images). Manual segmentations by two observers of six
T1w datasets (the PDw dataset is implicitly segmented
after rigid registration to the T1w datasets), that include
labels for GM, WM, CSF, and BG, were used as training
data [27, 33]. This brain tissue segmentation method has
been extensively evaluated within the context of the Rot-
terdam Scan Study, showing good accuracy and repro-
ducibility [33, 34]. An example of the automated tissue
segmentation is shown in Fig. 3.
To facilitate more regionalized analysis of total brain,
WM and GM volumes, individual lobes have been seg-
mented. This is achieved by non-rigidly registering a
template image in which the lobes have been manually
outlined [35–37]. Finally, T1-weighted MR images have
been used to calculate subcortical structures and thickness
of the cerebral cortex using a model-based automated
procedure using Freesurfer image analysis suite (http://sur
fer.nmr.mgh.harvard.edu/) [38, 39].
White matter lesion classification
The brain tissue segmentation methods described above
have been complemented with WML segmentation [40].
Hereto, both the brain tissue segmentation, and the FLAIR
image are used. In the brain tissue segmentation, possible
WMLs are misclassified as GM with a ring of WM voxels.
In the FLAIR image the WMLs are hyperintense. We
therefore process the histogram from the FLAIR image
The Rotterdam Scan Study: design update 2016 and main findings 1303
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intensities of all voxels that are classified as GM, to esti-
mate the mean and standard deviation of true GM voxels.
Subsequently, WML voxels are extracted by intensity
thresholding, where the threshold depends on the estimated
GM distribution. False positives are removed by excluding
voxels which are not sufficiently connected to the white
matter. The different parameters (intensity threshold, and
quantitative definition of not being sufficiently connected)
have been optimized on a large reference dataset. The
method has been quantitatively evaluated [40] and has
Fig. 2 Depiction of the images
acquired using the MRI
protocol. First row: T1-
weighted (a), proton-density-
weighted (b), and fluid
attenuated inversion recovery
(c) images. Second row: T2*-
weighted (d) image, sagittal
scout for the 2D phase contrast
measurement (e), and the
resulting flow image (f). Third
row: example of an image
acquired using diffusion
weighted imaging (g), map of
fractional anisotropy (h), map of
mean diffusivity (i), and resting-
state functional MRI (j)
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successfully been applied to the whole cohort [41]. Visual
inspection of the results indicates that the method is robust,
with approximately only 4 % of the scans containing false
positive or false negative WMLs. Figure 3 demonstrates
the automated WML segmentation result.
Brain structure segmentation and shape analysis
Within the Rotterdam Scan Study, we have developed a
graph cut framework for neurostructure segmentation [42]
combining atlas registration and statistical models of image
appearance [43], which currently has been implemented for
hippocampus segmentation. The developed framework
utilizes twenty manually outlined hippocampi (atlases)
[44], which are used both for atlas registration, and for
training the statistical image appearance models. The
twenty atlases are non-rigidly registered to an image to be
segmented, after which by averaging a spatial probability
map is obtained which indicates the likeliness of a voxel to
belong to the hippocampus. Within a graph cut framework,
this information is complemented by the likeliness that a
voxel is part of the hippocampus based on intensity
information, for obtaining a segmentation. The method has
been shown to improve on existing manual hippocampus
segmentation techniques [43], and has been applied to a
number of studies [45, 46]. Recently, we have extended the
hippocampus method to also include more informative
appearance models [47]. The graph cut framework devel-
oped for hippocampus segmentation has additionally been
used for ventricle segmentation [48], and segmentation of
the cerebellum [49, 50].
Based on the hippocampus segmentation, we also have
developed a method to quantify hippocampal shape, and
demonstrated that the combination of hippocampal volume
and hippocampal shape performed better on the prediction
of dementia than when just using volume [51].
Diffusion tensor imaging (DTI): global and tract-
based analysis
DTI enables measurement of the microstructural integrity
of white matter. Within the Rotterdam Scan Study, a
number of image analysis techniques have been employed
and developed for the analysis of DTI data. These include
conventional global and regional analysis of DTI-derived
measures such as Fractional Anisotropy (FA) and Mean
Diffusivity (MD) [52], and tract-based analysis of FA and
MD [53]. Global and regional analysis of FA and MD has
Fig. 3 Example of brain tissue segmentation. Left column
T1weighted sequence with k-nearest neighbor based tissue segmen-
tation into grey matter (orange), white matter (green), cerebrospinal
fluid (purple), and white matter lesions (red). Middle column: Proton-
density weighted sequence with similar tissue segmentation. Right
column FLAIR-sequence with white matter lesion segmentation
(pink)
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been performed using the FSL toolbox [54], and consisted
of Eddy current correction, head motion correction, skull
stripping and tensor model fitting. As discussed below, DTI
data were registered with the other imaging data to study
relations between atrophy, WMLs, and DTI-derived
measures.
Tract-based analysis of DTI enables a more localized
comparison of FA and MD between groups. In the Rot-
terdam Scan Study, tract-based analysis has been achieved
using tract-based spatial statistics (TBSS) [55] a technique
that creates a common skeleton of the white matter tracts
from a series of images, onto which for each individual the
local maximum FA value is projected. This enables robust
voxel-wise statistical analysis of the microstructural
integrity of white matter across persons [53].
Since the projection step in TBSS may break topological
consistency of the transformed images, we investigated
whether the correspondence step in TBSS could be
replaced by non-rigid registration. We evaluated perfor-
mance of non-rigid registration to the conventional TBSS
approach by performing tractography in native space and
measuring the ability of the correspondence step in creating
similarity in tractography results in 23 white matter struc-
tures in a common template space. It was shown that both
non-rigid registration using Elastix [56] and FMRIB’s
Nonlinear Image Registration Tool (FNIRT) [57] outper-
formed the conventional TBSS analysis [58]. Furthermore,
the approach enables the automatic analysis of diffusion
MRI characteristics in 23 white matter tracts. An example
of 23 automatically generated white matter tracts on a
subject of the Rotterdam Scan Study is shown in Fig. 4.
Diffusion tensor imaging: connectivity analysis
Using deterministic or probabilistic tractography, DTI can
also be used to study structural connectivity of the brain. In
order to compare structural connectivity across persons in
the Rotterdam Scan Study, we developed a novel frame-
work, SAMSCo, which enables construction of weighted
structural brain connectivity networks which can be
effectively analyzed using statistical methods [59, 60]. The
weighted networks are obtained using a minimum cost path
(mcp) method with an anisotropic local cost function based
on the locally estimated diffusion tensor weighted images.
Start and end regions of the mcp were defined by a Free-
surfer segmentation [61, 62] of subcortical structures and
cortical parcellation. Using a re-scan on 30 persons, good
reproducibility of the connectivity maps was shown [34].
Resting-state functional MRI: resting-state networks
Preprocessing and analysis of rs-fMRI data is performed
using the FMRIB software library (FSL, http://www.fmrib.
ox.ac.uk/fsl/). Resting-state fMRI volumes are registered to
the individual’s structural scan and standard space using
FNIRT [57]. A single-subject independent component
analysis (ICA) [63] approach is used to decompose the
acquired rs-fMRI data into various components of resting-
state activity in each participant. Low-frequency drifts and
motion components are handled with MCFLIRT and tem-
poral filtering [63, 64]. Next, we applied an automatic
component classification using FMRIB’s ICA-based
Xnoiseifier (FIX) for the discrimination between true signal
versus noise components [65, 66]. Next, using dual
regression [67], spatial maps of various resting-state net-
works, including the default mode network, are derived for
each participant. These maps are then used to generate
measures of functional connectivity and clusters of acti-
vation within each network, and later also to make voxel-
based comparisons.
Visual ratings
Scan quality and incidental findings
Each MRI scan that is acquired is visually examined by a
research physician in the Rotterdam Scan Study. During
this visual inspection, the MRI scan is rated for quality and
the presence and severity of motion artefacts or signal
Fig. 4 Example of the automatic analysis of diffusion MRI charac-
teristics in 23 white matter structures
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inhomogeneity (for example due to metallic implants) is
recorded. Furthermore, each scan is evaluated by trained
research physicians for presence of incidental findings, i.e.
abnormalities of potential clinical relevance that were
previously unknown, that are unexpected and that are
unrelated to the purpose of the scan [68, 69]. All potential
findings are recorded in a database and are in a later stage
evaluated by an experienced neuroradiologist. Referral of
participants for further medical examination occurs in
accordance with an expert-defined protocol [68].
Visual check of automated processing performance
Though post-processing for tissue segmentation and
structure segmentation takes places fully automated and
without user interaction, all end results are visually
checked for performance. For example, small motion
artefacts in the FLAIR sequence that do not necessitate
exclusion of an MRI scan may interfere with WML seg-
mentation and cause false positive lesions after automated
segmentation; or brain masking may result in minimal
inclusion of dura or skull. For manual inspection, a dedi-
cated tool has been developed in MevisLab enabling the
visualization of the original scan with the image processing
results (Fig. 5). Editing tools are available to adjust the
segmentations if necessary. After visual inspection, manual
editing of any errors is needed in less than 10 % of scans,
depending on the type of post-processing. Furthermore,
less than 1 % of scans are excluded based on artefacts that
are only discovered after automated post-processing (for
example motion or susceptibility artefacts in diffusion
tensor images, which are not apparent in the raw unpro-
cessed data).
Cerebral small vessel disease
Infarcts are rated on FLAIR, proton density-weighted, and
T1-weighted sequences. Lacunar infarcts are defined as
focal lesions C3 mm and\15 mm in size with the same
signal characteristics as CSF on all sequences, and (when
located supratentorially) with a hyperintense rim on the
FLAIR sequence [68]. Lesions C15 mm in size, but
otherwise similar, are rated as subcortical infarcts. Infarcts
showing involvement of cortical gray matter are classified
as cortical infarcts. We further distinguish cortical infarcts
into small and large infarcts based on their size [70].
All 3D T2* GRE scans are reviewed for the presence,
number, and location of cerebral microbleeds. Microbleeds
are defined as focal areas of very low signal intensity on
T2*-weighted imaging that are not accompanied by evident
signal abnormality on other structural sequences [71].
Microbleed location is categorized into one of three loca-
tions: lobar (cortical gray and subcortical or periventricular
white matter), deep (deep gray matter: basal ganglia and
thalamus, and the white matter of the corpus callosum,
internal, external, and extreme capsule), and infratentorial
(brainstem and cerebellum) [71]. Intraobserver and inter-
observer reliabilities for microbleed rating are very good
(j = 0.85–0.87 [72]) and review of the intial ratings by an
experienced neuroradiologist yielded very high accordance
as well [72].
Virchow-Robin spaces
Virchow-Robin spaces (VRS), or enlarged perivascular
spaces, are primarily rated on the PDw-sequence according
to a standardized protocol [73]. In short, VRS are identified
by their linear, ovoid, or round shape depending on the
slice direction and are considered dilated when their
diameter is C1 mm. VRS are assessed in 4 brain regions:
the semioval center, the basal ganglia, the hippocampi, and
the mesencephalon. Raters determine the amount of dilated
VRS for each region, with a maximum of 20 per region.
Because the semioval center and basal ganglia are visible
on multiple slices, the rating is done on a single, predefined
slice to decrease inter- and intrarater variability as descri-
bed previously [73]. In the hippocampus and mesen-
cephalon, all unique dilated VRS are counted. In 2013, we
initiated the UNIVRSE (Uniform Neuro-Imaging of Vir-
chow-Robin Spaces Enlargement)—consortium in order to
investigate causes and consequences of VRS on a large
scale [74].
Main findings
Cerebral small vessel disease
Already during the first round of MRI in the Rotterdam
Study we learned that markers of ischemic small vessel
disease such as WMLs and lacunar infarcts are highly
prevalent in the elderly and that these relate to cardiovas-
cular risk factors, such as hypertension or smoking [37, 75–
84]. In the MRI scans obtained from 2005 onwards, we
confirmed this frequent occurrence of WML and infarcts in
the elderly and extended the prevalence and volume esti-
mates to the middle aged population [68]. Moreover, we
found these cardiovascular risk factors to be associated
with a thinner cortex of the brain [85]. In addition to
studying the role of above-mentioned cardiovascular risk
factors in the development of ischemic small vessel dis-
ease, we also directly investigated associations of
atherosclerosis with these markers. Using arterial calcifi-
cation (measured with computed tomography) as an
established marker of atherosclerosis, we found
atherosclerotic calcification in various vessel beds, but
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especially in the intracranial vasculature, to be related to
WMLs, lacunar infarcts, and brain atrophy [86, 87].
Besides focusing on its risk factors, we have also started
investigating consequences of ischemic small vessel dis-
ease. In this light, we found that larger WML volumes and
lacunar infarcts are associated with a higher risk of mor-
tality [88], mild cognitive impairment [89], dementia [90],
and a higher risk of stroke [91]. More recently, we found
that larger WML volumes are associated with deterioration
and incident impairment in daily functioning [92].
Besides the ischemic lesions in the context of cerebral
small vessel disease, hemorrhagic lesions in the form of
cerebral microbleeds have gained rapid interest [71]. To
visualize cerebral microbleeds we use a dedicated 3D high-
resolution T2* GRE sequence, which we found to improve
the detection of cerebral microbleeds considerably in
comparison with a conventional MRI sequence [93]. When
we applied this high-resolution sequence in larger groups
of participants, we found that cerebral microbleeds are
present in 1 in 5 persons over age of 60 and in over 1 in 3 in
persons aged 80 years and older [72, 94]. This prevalence
is much higher than reported previously, which in part may
be explained by the use of this dedicated MRI sequence. In
a longitudinal study over an interval of 3–4 years, we
found that 10 % of persons developed new microbleeds
[95], and that this was highly dependent on the presence
and amount of mircobleeds at baseline.
With regard to risk factors for microbleeds we consis-
tently found that these vary according to the location of
microbleeds in the brain. Cardiovascular risk factors and
markers of ischemic small vessel disease are related to
deep or infratentorial microbleeds, whilst APOE genotype
relates to strictly lobar microbleeds [72, 94, 95]. This is
indirect evidence that deep or infratentorial microbleeds
result from arteriolosclerotic angiopathy, whereas strictly
lobar microbleeds are caused by cerebral amyloid
angiopathy [96].
The high prevalence of cerebral microbleeds and their
potential link with bleeding-prone microangiopathy raised
our interest in how these relate to antithrombotic drug use.
We found that persons who had used or were using
antithrombotic medication more often have cerebral
microbleeds [97, 98]. Moreover, we found that the use of
oral anticoagulants is associated with a higher incidence of
microbleeds [99]. With regard to consequences of
microbleeds, we found that the presence and amount of
microbleeds increases the risk of stroke and mortality [100,
101]. Especially microbleeds in locations suggestive of
amyloid angiopathy increase the risk of cerebral hemor-
rhages [101]. In addition, we found that microbleeds are
Fig. 5 Screenshot of the tool which enables the visualization of the
original scan with the image processing results. On the left screen, the
mask for total intracranial volume is shown. On the right screen the
rater can evaluate the tissue segmentation. In the lower panel, the
rater can indicate the quality of the mask, the brain tissue segmen-
tation and the white matter lesion segmentation
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associated with the progression of ischemic small vessel
disease and loss of white matter structural integrity [102,
103]. Finally, we also showed that the presence of
numerous microbleeds, especially in a strictly lobar loca-
tion, is associated with worse cognitive performance.
Adjustment for vascular risk factors and other imaging
markers of small vessel disease did not alter this associa-
tion [104], suggesting an independent role for microbleed-
associated vasculopathy in cognitive impairment.
Cerebral blood flow
Total cerebral blood flow (tCBF) and total brain perfusion
(tCBF per 100 ml brain tissue) were measured with 2D
phase contrast imaging as described above. We showed a
close relationship between tCBF and markers of the
microvasculature, e.g. retinal vessel diameters [75]. In 892
persons aged 60 years and older, we further showed that
determinants of tCBF and total brain perfusion differ lar-
gely, due to the large influence of brain volume on tCBF
values [105]. In a longitudinal study, we further investi-
gated the relation between brain volume and tCBF, and our
results indicate that brain atrophy likely causes the tCBF to
decrease over time, rather than vice versa [106].
When investigating determinants of tCBF, we found that
pulse pressure, body mass index, current smoking, and
kidney function importantly contribute to variations in tCBF
[105, 107]. Furthermore, persons with low total brain per-
fusion had significantly moreWMLs compared to those with
high total brain perfusion. The role of tCBF with cognitive
performance appeared more complex with brain atrophy
either confounding or mediating the association [108].
Finally, we found that the parenchymal CBF is higher is
persons with migraine during the attack-free period when
compared with persons without migraine, supporting the
idea of sustained vascular differences in migraineurs [109].
White matter microstructural integrity
We demonstrated that age-related changes in the normal-
appearing white matter are primarily but not exclusively
explained by white matter atrophy and formation of WMLs
[110]. Using tract-specific analyses, we found specific
white matter tracts including the commissural and limbic
tracts, to be most prominently affected by aging. Further-
more, we found that white matter atrophy and WML for-
mation related to loss of integrity in distinct brain regions,
indicating that the two processes are not sequential events
but are rather independent and thus pathophysiologically
potentially different [53]. Finally, we found that white
matter changes can already be quantified using DTI and
FLAIR before actual WML develop. This suggests that
WML develop gradually and that the WMLs that are
visible only represent a small portion of the underlying
white matter pathology [111].
We demonstrated that besides traditional cardiovascular
risk factors [110], intracranial carotid artery atherosclerosis
[87], cerebral microbleeds [102], and a reduced kidney
function [112], are all associated with loss of white matter
microstructural integrity.
We have found DTI parameters within WMLs and
normal-appearing white matter to be associated with cog-
nitive function, even when taking into account volume of
WMLs and white matter atrophy [52]. This indicates that
the deleterious effect of white matter changes on cognition
not only depends on lesion burden or amount of atrophy,
but also on characteristics that are not easily evaluated by
conventional MRI.
Imaging genetics
Since the advent of genome-wide association studies
(GWAS) we have been involved in numerous studies in
which the underlying genetics of various brain traits are
investigated [113]. We have for example contributed to the
identification of several single nucleotide polymorphisms
(SNPs) associated with intracranial volume [114], and
subcortical brain structures [115]. In collaboration with
research partners in the CHARGE consortium [116], we
performed a genome-wide association study of WML
burden and were able to identify 6 risk-associated SNPs on
chromosome 17q25 [117], which we subsequently repli-
cated in a separate Rotterdam Scan Study cohort [41].
More recently, we identified another set of novel genetic
loci implicating inflammation and glial proliferation in the
development of WML [118]. Similar analyses have been
undertaken for brain infarcts [119]. Moreover, we found
that several risk variants of Alzheimer’s disease and fron-
totemporal dementia are also associated with smaller total
brain volume and hippocampal volume [120], and the
volume of temporal brain regions [121].
For additional EJE references on determinants of com-
mon neurological disorders see [122–136].
Incidental findings
The large-scale acquisition of brain MRI comes with the
detection of incidental findings [68]; abnormalities of
potential clinical relevance unrelated to the purpose of the
examination [137]. After scanning 2000 participants we
found that the most frequent findings in the Rotterdam
Scan Study are aneurysms (1.8 %) and benign primary
tumors (meningiomas) (1.6 %) [68]. Currently, we are
updating these numbers after scanning over 8500 partici-
pants, and evaluate the clinical management and natural
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course of these findings. This information may then serve
as basis on which future recommendations for handling
incidental findings in both the clinical setting and in
research studies may be based.
For further EJE references on the handling of incidental
findings in large-scale imaging studies see [138–141].
Future perspectives
The Rotterdam Scan Study provides a unique environment
to study the etiology of neurological diseases in the elderly.
Over 5800 persons have already undergone brain MRI-
scanning and in coming years repeated waves of follow-up
examination will ensure a wealth of imaging data, espe-
cially from a longitudinal perspective. Until recently, the
focus of our research has been mainly on the identification
of risk factors and determinants of brain pathology. More
recently, we have been examining the contribution of the
various risk factors as discussed above and of novel risk
factors with regard to the potential for prevention of stroke
and dementia [142, 143]. In addition, we have also
extended our scope of common neurological disorders to
Parkinson’s disease (for further EJE references on
Parkinson’s disease see [124, 144–149]), and for gait dis-
orders see [92, 150–152]. In particular, our focus will
include changes on brain imaging that relate to these
conditions. Moreover, in the coming years, we plan to
broaden our research in several ways, including the use of
novel image sequences, novel post-processing techniques,
and the identification of novel risk factors, and the mech-
anisms through which various lifestyle or genetic factors
influence clinical outcomes through brain changes.
Currently, we are investigating the feasibility of adding
perfusion imaging in the form of arterial spin labeling
(ASL) to the scan protocol of the Rotterdam Scan Study.
This will allow us to explore the interplay of structural and
functional measures with (regional) brain perfusion. This is
in particular of interest as perfusion may precede actual
changes in structure or even function and could thus
potentially be a very early marker of pathology.
Regarding new imaging markers, we are currently
studying the prevalence and clinical correlates of small
cortical brain infarcts in our population. In our initial report
on these infarcts, we found that these are prevalent in
1.1 % of the population and are associated with cardio-
vascular risk factors [70]. Our interest in these small cor-
tical infarcts arose from the current attention for cortical
microinfarcts—microscopic small infarcts seen on patho-
logic exams—as potential new markers of cerebrovascular
disease and indicators of cognitive impairment. Though
larger in size, the small cortical infarcts that can be iden-
tified on MRI may be reflecting pathology similar to these
microscopic lesions and are therefore of interest for further
research.
Another important focus of our research will be on
functional connectivity as new imaging marker in neu-
rodegenerative disease. Currently, we are finalizing the rs-
fMRI data analysis pipeline, and expect that end-2015 we
will initiate the investigation of determinants and correlates
of functional connectivity.
With regard to the MRI-scanner, we acknowledge that
the ongoing hardware developments will necessitate
upgrading of the scanner. Although there are no current
plans to change the scanner, we foresee upgrading to a 3 T
scanner in coming years.
Standardized and evaluated automated image processing
techniques are crucial in exploiting the rich information
that is available in population imaging data. They have
enabled a transition from qualitative image interpretation
into quantitative imaging. Quantitative imaging is non-
trivial; it requires standardization and optimization in all
the steps from data acquisition, to data analysis in struc-
tured reporting. In the next years, the number of validated
quantitative image analysis techniques will further
increase, also including more complex measures. Also, the
results of these analyses will increasingly be stored in a
standardized manner. This will enable a richer characteri-
zation of brain anatomy, pathology, connectivity and
function. Relating these quantitative image measures to
disease status, progression and events, will be a powerful
tool for development of novel diagnostic and prognostic
quantitative imaging biomarkers.
The standardization of image acquisition and processing
protocols also implies that high quality reference data are
being acquired. We are working on a novel IT-infrastruc-
ture in which we use the various standardized analysis
pipelines to create a well-defined library of imaging
biomarkers. We foresee two main advantages of this
strategy. First, this standardized and well-defined library of
biomarker analyses may be used by other researchers.
Second, the high quality data provide unique reference
databases on numerous biomarkers, which may eventually
serve as basis for use in a clinical setting to contrast find-
ings in an individual with a reference population.
As already mentioned before, the concomitant continu-
ous monitoring of all participants in the Rotterdam Study
ensures that we have a wealth of clinical data available,
including cognitive performance [125] and the occurrence
of dementia and stroke. In the coming years we intend to
expand our research on how MRI markers of brain
pathology relate to these clinical outcomes. Finally, we
intend to expand our (inter)national collaborations in the
field of population-imaging and imaging genetics to further
unravel the causes and consequences of neurological dis-
eases in the elderly.
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